MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2018-10-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

NCT04054986

Breast Cancer

COMPLETED PHASE1

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

NCT04332588

HER2-positive Breast Cancer

RECRUITING PHASE1

Intensity Modulated Radiotherapy for Breast Cancer

NCT00594477

Breast Cancer

COMPLETED PHASE1

Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging

NCT03568448

HER2 Negative Breast Cancer

ACTIVE_NOT_RECRUITING

Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer

NCT00107484

Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is conducted over two phases.

Pilot Phase: This study will enroll approximately 12 patients, up to 20 in total in the Pilot Phase and 30 patients in the Expansion Phase. The first three patients that are enrolled in the Pilot Phase can have any solid tumor type; however subsequent patients must have Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), Triple negative breast cancer (TNBC), Estrogen Receptor/Progesterone Receptor (ER/PR) positive breast cancer, pancreatic cancer, ovarian cancer, gastric cancer, gastro-oesophageal junction adenocarcinoma or head and neck cancer. No more than three patients with ER/PR positive breast cancer can be enrolled in the Pilot Phase and similar restrictions may be placed on other tumor types to ensure a heterogeneous population.

Expansion Phase: The expansion will enroll patients with advanced metastatic breast cancer into three cohorts of 10 patients each depending on sub-type of breast cancer:

Cohort 1: ER and/or PR-positive breast cancer Cohort 2: TNBC Cohort 3: BC with active brain metastasis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors ER/PR Positive Breast Cancer Triple Negative Breast Cancer Metastatic Breast Cancer With Active Brain Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pilot Phase: Ferumoxytol followed by MM-398

Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle

Group Type EXPERIMENTAL

Ferumoxytol

Intervention Type DRUG

Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.

MM-398

Intervention Type DRUG

MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity

Expansion Phase: Ferumoxytol followed by MM-398

Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis

Group Type EXPERIMENTAL

Ferumoxytol

Intervention Type DRUG

Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.

MM-398

Intervention Type DRUG

MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ferumoxytol

Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.

Intervention Type DRUG

MM-398

MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All subjects:

* Pathologically confirmed diagnosis of solid tumors
* Metastatic disease
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1
* Adequate bone marrow, hepatic and renal function
* Normal Electrocardiogram (ECG)
* 18 years of age or above
* Able to understand and sign informed consent

Pilot study only:

\- CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer

Expansion Phase Additional Criteria:

* Locally advanced or metastatic breast cancer
* Received at least one cytotoxic therapy in the locally advanced and metastatic setting
* Received ≤ 5 prior lines of chemotherapy in the metastatic setting
* Candidate for chemotherapy

* Breast cancer with active brain metastasis
* Neurologically stable

Exclusion Criteria

* Active Central nervous system (CNS) metastasis (applies to pilot phase and expansion phase cohort 1 and 2 only)
* Clinically significant GI disorders
* Prior irinotecan or bevacizumab therapy within last 6 months and for Expansion Phase patients, have received any prior treatment with Topol inhibitor
* Known hypersensitivity to MM-398 or ferumoxytol
* Inability to undergo MRI
* Active infection
* Pregnant or breast feeding
* Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent, whichever is longer, prior to the first scheduled day of dosing in this study
* Received radiation therapy in the last 14 days
* Treated with parenteral iron in the previous 4 weeks

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No